文献速递神经肿瘤

H3 G34突变型弥漫性半球胶质瘤的临床与分子特征

The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant.
PubMed 文献 · Neuro Oncol · 2025-01-01

该回顾性队列纳入114例H3 G34突变型弥漫性半球胶质瘤(WHO 4级)患者,中位年龄22岁,分析其影像、组织学和分子特征。中位生存期21.5个月,女性、全切除和MGMT启动子甲基化与预后较好相关,无软脑膜侵犯、微血管增生和CDK6扩增也与预后相关。

要点

  • H3 G34突变型弥漫性半球胶质瘤中位生存期21.5个月。
  • 女性、全切除和MGMT启动子甲基化与较好预后相关。
  • 无软脑膜侵犯、微血管增生和CDK6扩增与较好预后相关。

核心结论

  • 本研究细化了H3 G34突变型弥漫性半球胶质瘤的临床与分子特征,亟需针对该新型肿瘤类型的专门试验。

研究设计与样本

  • 回顾性队列研究,纳入114例H3 G34突变型弥漫性半球胶质瘤、中枢神经系统WHO 4级患者,中位年龄22岁,分析肿瘤影像、组织学和分子特征。

主要发现

  • 与胶质母细胞瘤相比,H3 G34突变型弥漫性半球胶质瘤在MRI上对比增强、坏死和水肿较少。
  • 突变和DNA拷贝数分析显示TP53和ATRX反复突变、CDKN2A/B纯合缺失以及PDGFRA、EGFR、CCND2和MYCN扩增。
  • 79例肿瘤(75%)检测到MGMT启动子甲基化;11例肿瘤(13%)显示10q26.3上涉及MGMT基因座的局限缺失的DNA拷贝数图谱。
  • 中位生存期为21.5个月;单因素分析中女性、全切除和MGMT启动子甲基化为有利预后因素。
  • 影像、病理和分子特征中,无软脑膜侵犯以及存在微血管增生和CDK6扩增在单因素分析中为有利预后因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diffuse hemispheric glioma, histone 3 (H3) G34-mutant, has been newly defined in the 2021 World Health Organization (WHO) classification of central nervous system tumors. Here we sought to define the prognostic roles of clinical, neuroimaging, pathological, and molecular features of these tumors. METHODS: We retrospectively assembled a cohort of 114 patients (median age 22 years) with diffuse hemispheric glioma, H3 G34-mutant, central nervous system WHO grade 4, and profiled the imaging, histological, and molecular landscape of their tumors. RESULTS: Compared with glioblastoma, H3 G34-mutant diffuse hemispheric gliomas exhibited less avid contrast enhancement, necrosis, and edema on MRI. Comprehensive analyses of mutational and DNA copy number profiles revealed recurrent mutations in TP53 and ATRX, homozygous deletions of CDKN2A/B, and amplifications of PDGFRA, EGFR, CCND2, and MYCN. MGMT promoter methylation was detected in 79 tumors (75%); 11 tumors (13%) showed DNA copy number profiles suggestive of circumscribed deletions on 10q26.3 involving the MGMT locus. Median survival was 21.5 months. Female sex, gross total resection, and MGMT promoter methylation were positive prognostic factors on univariate analysis. Among radiological, pathological, and molecular features, the absence of pial invasion and the presence of microvascular proliferation and CDK6 amplification were positive prognostic factors on univariate analyses. CONCLUSIONS: This study refines the clinical and molecular landscape of H3 G34-mutant diffuse hemispheric gliomas. Dedicated trials for this novel tumor type are urgently needed.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Le Rhun E, Bink A, Felsberg J, et al. The clinical and molecular landscape of diffuse hemispheric glioma, H3 G34-mutant. Neuro Oncol. 2025. PMID: 39842935. doi:10.1093/neuonc/noaf015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。